2023年1月27日 · Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes.

MSCs移植作为一种微创或无创生物治疗，具有低感染、低风险的特点， 可促进IBD患者的肠道黏膜愈合，降低CDAI、 PDAI和Mayo评分，改善患者临床症状，提高生活质量，具有很大的治疗潜力。

2024年5月22日 · In the latest clinical trials, the safety and efficacy of MSCs in the treatment of IBD have been confirmed by transfusion of autologous or allogeneic bone marrow, umbilical cord, and adipose MSCs, as well as their derived extracellular vesicles.

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is an inflammatory autoimmune disease characterized by T-cell infiltration to the colon. Mesenchymal stem cells (MSCs) have the potential to rescue IBD owing to …

2015年12月1日 · In this review, we will discuss the biologic rationale that makes MSCs a promising therapeutic tool for IBD, and analyze recent experimental and clinical findings, highlighting current limitations and future perspectives of MSCs-related immunotherapy for IBD.

最近，鉴于其免疫调节和促生存属性，间充质干细胞/基质细胞 （MSCs） 疗法已成为治疗炎症性肠病 （IBD） 的新兴治疗方式。 MSC 通过分泌多种抗炎介质来缓解失调的炎症反应，例如白细胞介素 10 （IL-10）、转化生长因子-β （TGFβ）、前列腺素 E2 （PGE2）、肿瘤坏死因子刺激基因 6 （TSG-6） 等。 事实上，IBD 的 MSC 治疗主要通过局部微循环构建、定植和修复以及免疫调节进行，从而减轻疾病的严重程度。 临床治疗效果取决于活的 MSC 通过旁分泌机制显着分泌各 …

We justify the use of MSC-based cell therapy as a novel strategy for IBD, discuss the biological roles that MSCs play underlying their therapeutic effects focusing on their immune-suppressive effects, illustrate methods to improve MSCs for better repair, and pinpoint the obstacles hindering their success and the challenges to overcome before ...

2021年6月4日 · MSCs移植作为一种微创或无创生物治疗，具有低感染、低风险的特点，可促进IBD患者的肠道黏膜愈合，降低CDAI、 PDAI和Mayo评分，改善患者临床症状，提高生活质量，具有很大的治疗潜力。

2022年12月1日 · Mesenchymal stem cells (MSCs) are a new therapeutic strategy for inflammatory bowel disease (IBD), and their efficacy has been widely recognized. However, there are...

2022年6月1日 · MSCs, MSC-driven exosomal microRNAs and MSC-based drug delivery systems have been demonstrated to affect immune system modulation in experimental animal models of IBD (Th17 suppression versus T-regular cell biased responses).